During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Pfizer Inc. PFE
- Dividend Yield: 5.88%
- Barclays analyst Carter Gould maintained an Equal-Weight rating and raised the price target from $30 to $32 on July 31. This analyst has an accuracy rate of 60%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and boosted the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.
- Recent News: On Monday, Pfizer released top-line safety and immunogenicity results from substudy B of the ongoing pivotal MONeT Phase 3 trial,evaluating two doses of Abrysvo vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus-associated lower respiratory tract disease.
- Benzinga Pro’s real-time newsfeed alerted to latest PFE news
GSK plc GSK
- Dividend Yield: 3.80%
- Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 70%.
- Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%.
- Recent News: On July 31, GSK reported second-quarter sales of $9.95 billion (7.88 billion Sterling Pounds), up 10% year-over-year and 13% on constant currency..
- Benzinga Pro’s charting tool helped identify the trend in GSK stock.
CVS Health Corporation CVS
- Dividend Yield: 4.66%
- Deutsche Bank analyst George Hillmaintained a Hold rating and cut the price target from $64 to $63 on Aug. 9. This analyst has an accuracy rate of 60%.
- Barclays analyst Andrew Mok maintained an Equal-Weight rating and slashed the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 66%.
- Recent News: On Aug. 7, CVS Health reported mixed second-quarter earnings and cut annual profit guidance.
- Benzinga Pro’s signals feature notified of a potential breakout in CVS shares.
Read More:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
